Dayspring Pharma's CG2001 Foam Meets Primary Endpoint in Phase II Male Pattern Baldness Trial

Key Takeaways

• CG2001 foam successfully met its primary endpoint in Phase II trial for androgenetic alopecia treatment
• Study demonstrated statistically significant and clinically meaningful results with favorable safety profile in 110 Chinese men
• Positive results position CG2001 as potential new treatment option for male pattern baldness, advancing toward Phase III trials

---

BEIJING, April 21, 2026 — Dayspring Pharma announced positive top-line results from its Phase II clinical trial evaluating CG2001 foam for treating androgenetic alopecia (AGA) in Chinese adult men, marking a significant milestone in male pattern baldness treatment development.

Trial Design and Results

The multicenter, randomized, double-blind, placebo-controlled Phase II study enrolled 110 Chinese adult men with androgenetic alopecia. Led by researchers at Peking University People’s Hospital, the trial successfully met its primary endpoint while demonstrating both statistical significance and clinical meaningfulness.

The study’s favorable efficacy and safety profile positions CG2001 foam as a promising therapeutic option for men experiencing male pattern baldness, a condition affecting millions worldwide.

Market Impact and Treatment Landscape

Androgenetic alopecia represents one of the most common forms of hair loss, affecting approximately 50% of men over age 50. Current treatment options remain limited, with existing therapies showing variable efficacy and potential side effects.

CG2001’s foam formulation offers potential advantages in terms of application convenience and patient compliance compared to traditional topical solutions or oral medications currently available in the market.

Next Steps and Development Timeline

With successful Phase II completion, Dayspring Pharma is expected to advance CG2001 into Phase III development. The company will likely engage with regulatory authorities to discuss trial design and endpoints for the pivotal study phase.

The positive results in the Chinese population may also support expansion into other geographic markets, potentially accelerating global development timelines for this novel androgenetic alopecia treatment.

Clinical Significance

The statistically significant results suggest CG2001 foam demonstrated measurable hair regrowth or hair loss prevention compared to placebo. The favorable safety profile indicates the treatment was well-tolerated among study participants, addressing a key concern for chronic dermatological treatments.

This development represents important progress in addressing unmet medical needs for men experiencing androgenetic alopecia, particularly in Asian populations where treatment options may be limited.

---

Frequently Asked Questions

What does this mean for patients with male pattern baldness?

The positive Phase II results suggest CG2001 foam could become a new treatment option for androgenetic alopecia, potentially offering improved efficacy or convenience compared to existing therapies. However, the treatment still requires Phase III testing before potential regulatory approval.

When will CG2001 foam be available to patients?

CG2001 foam is not yet commercially available. Following these Phase II results, Dayspring Pharma will likely initiate Phase III trials, which typically take 1-3 years to complete. If successful, regulatory review could add another 1-2 years before potential market availability.

How does CG2001 compare to existing hair loss treatments?

While specific comparative data wasn’t disclosed, CG2001’s foam formulation may offer application advantages over current topical solutions like minoxidil. The trial’s positive efficacy and safety results suggest it could be competitive with existing treatments, but head-to-head studies would be needed for direct comparison.